2,5-二溴-4-甲基噻唑 | 79247-78-2

• 物质功能分类: 香精与香料 - 合成香料 - 内酯和含氧杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2,5-二溴-4-甲基噻唑
• 英文名称: 2,5-dibromo-4-methylthiazole
• 英文别名: 2,5-dibromo-4-methyl-1,3-thiazole
• CAS: 79247-78-2
• 化学式: C₄H₃Br₂NS
• mdl: MFCD09260910
• 分子量: 256.949
• InChiKey: PVJMZIKWTNQXKO-UHFFFAOYSA-N

物化性质

• 熔点：
  22 °C
• 沸点：
  260.7±20.0 °C(Predicted)
• 密度：
  2.127±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934100090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P301+P310
• 危险品运输编号：
  2811
• 危险性描述：
  H301

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 2,5-Dibromo-4-methylthiazole
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 79247-78-2
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
Serious eye damage (Category 1), H318
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25, R41
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
H318 Causes serious eye damage.
Precautionary statement(s)
P280 Wear protective gloves/ eye protection/ face protection.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C4H3Br2NS
Molecular Weight : 256,95 g/mol
CAS-No. : 79247-78-2
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
2,5-Dibromo-4-methylthiazole
CAS-No. 79247-78-2 Acute Tox. 3; Eye Dam. 1; <= 100 %
H301, H318
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
2,5-Dibromo-4-methylthiazole
CAS-No. 79247-78-2 T, R25 - R41 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Sulphur oxides, Hydrogen bromide gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 1,829
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (2,5-Dibromo-4-methylthiazole)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (2,5-Dibromo-4-methylthiazole)
IATA: Toxic solid, organic, n.o.s. (2,5-Dibromo-4-methylthiazole)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
Eye Dam. Serious eye damage
H301 Toxic if swallowed.
H318 Causes serious eye damage.
Full text of R-phrases referred to under sections 2 and 3
T Toxic
R25 Toxic if swallowed.
R41 Risk of serious damage to eyes.
Further information
Copyright 2013 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  苯并恶唑 、 2,5-二溴-4-甲基噻唑 在 PdCl(C₃H₅)(dppb) 、 caesium carbonate 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 24.0h， 以42.04%的产率得到
  参考文献：
  名称：

  벤조옥사졸 유도체 및 이를 포함하는 형광재료

  摘要：

  本发明涉及如下所示的苯并噁唑衍生物。因此，可以提供一种荧光材料，其荧光量得到显着改善，染色性和分散性优异，并且通过减少使用量来最小化环境污染并提高经济性。【结构式1】

  公开号：

  KR20210081549A
• 作为产物：
  描述：

  2-氨基-4-甲基噻唑 在 氢溴酸 、 sodium nitrite 作用下， 生成 2,5-二溴-4-甲基噻唑
  参考文献：
  名称：

  Takeda et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1947, vol. 67, p. 193

  摘要：

  DOI：

文献信息

• Viral polymerase inhibitors
  申请人：Boehringer Ingelheim (Canada) Ltd.

  公开号：US20030236251A1

  公开（公告）日：2003-12-25

  An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: 1 wherein R 1 is selected from: H, haloalkyl, (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 3-7 )cycloalkyl, (C 2-6 )alkynyl, (C 5-7 )cycloalkenyl, 6 or 10-membered aryl, Het all optionally substituted; R 2 is selected from (C 1-6 )alkyl, (C 3-7 )cycloalkyl, (C 6-10 )bicycloalkyl, 6- or 10-membered aryl, or Het all optionally substituted; B is N or CR 5 , wherein R 5 is H, halogen, haloalkyl, (C 1-6 )alkyl, (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl; X is N or CR 5 ; D is N or CR 5 ; each of Y 1 and Y 2 is independently O or S; Z is O, N, or NR z wherein R z is H, (C 1-6 )alkyl, (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl; R 3 and R 4 are each independently H, (C 1-6 )alkyl, first (C 3-7 )cycloalkyl or 6- or 10-membered aryl, Het (C 1-6 )alkyl-6- or 10-membered aryl, (C 1-6 )alkyl-Het; or each R 3 and R 4 are independently covalently bonded together to form second (C 3-7 )cycloalkyl, or heterocycle, all optionally substituted; or when Z is N, either R 3 or R 4 are independently covalently bonded thereto to form a nitrogen-containing heterocycle; R 7 is H, (C 1-6 alkyl), (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl; or R 7 is covalently bonded to either of R 3 or R 4 to form a heterocycle; A is (C 1-6 ) alkyl-CONHR 8 wherein R 8 is-6- or 10-membered aryl, or Het; or A is a 6- or 10-membered aryl, or Het said aryl or Het being optionally substituted; or a salt or a derivative thereof; such compounds being potent inhibitors of HCV NS5B polymerase.

  公式I所代表的化合物的异构体、对映体、非对映异构体或互变异构体，其中R1选自：H、卤代烷基、(C1-6)烷基、(C2-6)烯基、(C3-7)环烷基、(C2-6)炔基、(C5-7)环烯基、6或10元芳基、Het均可选择性地取代；R2选自(C1-6)烷基、(C3-7)环烷基、(C6-10)双环烷基、6-或10元芳基、或Het均可选择性地取代；B为N或CR5，其中R5为H、卤素、卤代烷基、(C1-6)烷基、(C3-7)环烷基或(C1-6)烷基-(C3-7)环烷基；X为N或CR5；D为N或CR5；Y1和Y2中的每一个独立地为O或S；Z为O、N或NRz，其中Rz为H、(C1-6)烷基、(C3-7)环烷基或(C1-6)烷基-(C3-7)环烷基；R3和R4各自独立地为H、(C1-6)烷基、第一(C3-7)环烷基或6-或10元芳基、Het(C1-6)烷基-6-或10元芳基、(C1-6)烷基-Het；或每个R3和R4独立地共价结合在一起形成第二(C3-7)环烷基，或杂环，均可选择性地取代；或当Z为N时，R3或R4中的任一者独立地与之共价结合形成含氮杂环；R7为H、(C1-6烷基)、(C3-7)环烷基或(C1-6)烷基-(C3-7)环烷基；或R7与R3或R4中的任一者共价结合形成杂环；A为(C1-6)烷基-CONHR8，其中R8为6-或10元芳基，或Het；或A为6-或10元芳基，或Het所述芳基或Het可选择性地取代；或其盐或衍生物；这类化合物是HCV NS5B聚合酶的有效抑制剂。
• Preparation of thiazolo (2,3-b) zuinazolones
  申请人：BASF Aktiengesellschaft

  公开号：US05030727A1

  公开（公告）日：1991-07-09

  The process of manufacturing thiazolo-(2,3-b)-quinoazolones of the formula I ##STR1## where R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are defined in the disclosure, wherein either a) an anthranilamide derivative of the formula II ##STR2## where R.sup.5 and R.sup.6 are hydrogen or C.sub.1 -C.sub.4 -alkyl, is reacted with a thiazole derivative of the formula III ##STR3## where X is fluorine, chlorine, bormine, alkylsulfonyl or arylsulfonyl, or b) for certain radicals R.sup.4' from the group R.sup.4 - a thiazolo-(2,3-b)-quinazolone of the general formula IV ##STR4## is reacted with a nucleophile R.sup.4' -H, where R.sup.4' is alkoxy, alkylthio or unsubstituted or halogen-, alkyl-, haloalkyl-, nitro- or alkoxy-substituted phenoxy or thiophenyl, or an alkali metal, alkaline earth metal or ammonium salt of an alcohol.

  制造式I的噻唑并[2,3-b]喹唑酮的过程如下：其中R.sup.1、R.sup.2、R.sup.3和R.sup.4在披露中有定义，其中a)式II的蒽酰胺衍生物与式III的噻唑衍生物发生反应，其中R.sup.5和R.sup.6为氢或C.sub.1-C.sub.4-烷基，其中X为氟、氯、溴、烷基磺酰基或芳基磺酰基；或b)对于来自R.sup.4组的某些基团R.sup.4'，通式IV的噻唑并[2,3-b]喹唑酮与亲核试剂R.sup.4'-H发生反应，其中R.sup.4'为烷氧基、烷基硫醚基或未取代或卤代、烷基、卤代烷基、硝基或烷氧基取代的苯氧基或硫代苯基，或醇的碱金属、碱土金属或铵盐。
• Substituted 1-propiolylpiperazine compounds, their preparation and use
  申请人：Kuhnert Sven

  公开号：US20070112011A1

  公开（公告）日：2007-05-17

  Substituted 1-propiolylpiperazine compounds corresponding to formula I in which X denotes N or C—R 2 , and n is an integer from 0 to 8, a method for producing such substituted 1-propiolylpiperazine compounds, pharmaceutical compositions containing such substituted 1-propiolylpiperazine compounds, and the use of such substituted 1-propiolylpiperazine compounds for modulating mGluR5 receptor activity or for treating or inhibiting pain and various other conditions, especially conditions at least partly mediated by the mGluR5 receptor.

  将符合公式I的1-丙炔基哌嗪化合物替代为X代表N或C—R，n为0至8的整数，一种生产这种替代的1-丙炔基哌嗪化合物的方法，含有这种替代的1-丙炔基哌嗪化合物的药物组合物，以及利用这种替代的1-丙炔基哌嗪化合物调节mGluR5受体活性或用于治疗或抑制疼痛和其他各种病症，特别是至少部分由mGluR5受体介导的病症。
• Reductive Alkylation of 2-Bromoazoles via Photoinduced Electron Transfer: A Versatile Strategy to C<i>sp</i>²–C<i>sp</i>³ Coupled Products
  作者：Amandeep Arora、Kip A. Teegardin、Jimmie D. Weaver

  DOI：10.1021/acs.orglett.5b01711

  日期：2015.8.7

  reductive coupling of aryl bromides with unactivated alkenes is introduced as a convenient method that circumvents any need for synthesis of sp3-hybridized coupling partners. The reaction takes place via photoinduced electron transfer from a tertiary amine to an aryl bromide that fragments to provide an aryl radical and subsequently reacts with an alkene to form a C–C bond. Conveniently, the amine also

  在催化技术的最前沿，获得C sp 2 –C sp 3偶联产物是一个具有挑战性的目标。芳基溴化物与未活化的烯烃的光催化还原偶联被引入作为一种方便的方法，该方法避免了合成sp 3-杂化偶联伴侣的任何需要。反应是通过光诱导的电子从叔胺到芳基溴的转移而发生的，后者分裂成芳基，然后与烯烃反应形成C-C键。胺也方便地用作最终的还原剂。该方法操作简单，对官能团具有耐受性，并且具有选择性，可以在复杂分子合成的背景下使用。
• Photocatalytic Generation of 2-Azolyl Radicals: Intermediates for the Azolylation of Arenes and Heteroarenes via C–H Functionalization
  作者：Amandeep Arora、Jimmie D. Weaver

  DOI：10.1021/acs.orglett.6b01718

  日期：2016.8.19

  2-bromoazoles via photocatalysis, is a powerful intermediate for the intermolecular arylation of unmodified (hetero)arenes. The reaction is characterized by mild conditions, operational simplicity, tolerance toward functional and sterically demanding groups, broad scope, and anti-Minisci selectivity. A working mechanism is provided, and a low-solubility amine is essential for successful coupling. The utility

  由2-溴唑通过光催化产生的2-偶氮基自由基是未修饰（杂）芳烃分子间芳基化的有力中间体。该反应的特征在于条件温和，操作简单，对官能团和空间要求高的基团的耐受性，范围广和抗Minisci选择性。提供了一种工作机制，并且低溶解度的胺对于成功偶联至关重要。该反应的实用性通过甲基雌酮的后期官能化和向其他溴代芳烃的应用证明。